EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children

Expertenkonsens zur Diagnose und Behandlung von makrolidresistenter Mycoplasma-pneumoniae-Pneumonie bei Kindern

Ying-Shuo Wang, Yun-Lian Zhou, Guan-Nan Bai, Shu-Xian Li, Dan Xu, Li-Na Chen, Xing Chen, Xiao-Yan Dong, Hong-Min Fu, Zhou Fu, Chuang-Li Hao, Jian-Guo Hong und 17 weitere

World Journal of Pediatrics · 2024-09 · 20 (9) · 901-914

DOI: 10.1007/s12519-024-00831-0 ↗

Auf einen Blick

Der Konsens beschreibt Diagnose und Behandlung von MRMP bei Kindern. Hervorgehoben werden frühe Identifikation, Laboruntersuchungen und der Einsatz von Zweitlinienantibiotika bei Therapieversagen.

Fragestellung

Wie sollen Diagnose und Behandlung der makrolidresistenten Mycoplasma-pneumoniae-Pneumonie (MRMP) bei Kindern erfolgen?

Methode

Expertenkonsens von 29 chinesischen pädiatrischen Experten auf Basis von Evidenzsuche in mehreren Datenbanken.

Ergebnisse

Betont werden Epidemiologie, Pathogenese, klinische Manifestationen, frühe Identifikation, Laboruntersuchungen, Antibiotikagabe, Glukokortikoide, intravenöse Immunglobuline und Bronchoskopie. PCR und Fluoreszenzsonden können Genmutationen früh erkennen.

Schlussfolgerung der Autor:innen

Der Konsens soll wissenschaftliche Orientierung für Diagnose und Behandlung von MRMP bei Kindern bieten. Weitere Studien zu Tetracyclinen und Chinolonen bei Kindern sind nötig; eine Antibiotika-Rotation wird als notwendig genannt.

Kernaussagen

  • Frühe Identifikation von MRMP-Genmutationen ist per PCR möglich
  • Zweitlinienantibiotika wie Tetracycline und Chinolone bleiben in vitro wirksam
  • Weitere Studien zu Wirkung auf Wachstum und Entwicklung sind erforderlich

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Übersichtsarbeit in der Zeitschrift World Journal of Pediatrics, online erschienen am 14.08.2024. Verfasst von Ying-Shuo Wang und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou …. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Drug Resistance, Bacterial, Macrolides, Mycoplasma pneumoniae. Die Arbeit wurde bisher 166-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key R & D Projects of Zhejiang Province.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mycoplasma pneumoniae ( M. pneumoniae ) is a significant contributor to community-acquired pneumonia among children. Since 1968, when a strain of M. pneumoniae resistant to macrolide antibiotics was initially reported in Japan, macrolide-resistant M. pneumoniae (MRMP) has been documented in many countries worldwide, with varying incidence rates. MRMP infections lead to a poor response to macrolide antibiotics, frequently resulting in prolonged fever, extended antibiotic treatment, increased hospitalization, intensive care unit admissions, and a significantly higher proportion of patients receiving glucocorticoids or second-line antibiotics. Since 2000, the global incidence of MRMP has gradually increased, especially in East Asia, which has posed a serious challenge to the treatment of M. pneumoniae infections in children and attracted widespread attention from pediatricians. However, there is still no global consensus on the diagnosis and treatment of MRMP in children.

Methods

We organized 29 Chinese experts majoring in pediatric pulmonology and epidemiology to write the world’s first consensus on the diagnosis and treatment of pediatric MRMP pneumonia, based on evidence collection. The evidence searches and reviews were conducted using electronic databases, including PubMed, Embase, Web of Science, CNKI, Medline, and the Cochrane Library. We used variations in terms for “macrolide-resistant”, “ Mycoplasma pneumoniae ”, “MP”, “ M. pneumoniae ”, “pneumonia”, “MRMP”, “lower respiratory tract infection”, “ Mycoplasma pneumoniae infection”, “children”, and “pediatric”.

Results

Epidemiology, pathogenesis, clinical manifestations, early identification, laboratory examination, principles of antibiotic use, application of glucocorticoids and intravenous immunoglobulin, and precautions for bronchoscopy are highlighted. Early and rapid identification of gene mutations associated with MRMP is now available by polymerase chain reaction and fluorescent probe techniques in respiratory specimens. Although the resistance rate to macrolide remains high, it is fortunate that M. pneumoniae still maintains good in vitro sensitivity to second-line antibiotics such as tetracyclines and quinolones, making them an effective treatment option for patients with initial treatment failure caused by macrolide antibiotics.

Conclusions

This consensus, based on international and national scientific evidence, provides scientific guidance for the diagnosis and treatment of MRMP in children. Further studies on tetracycline and quinolone drugs in children are urgently needed to evaluate their effects on the growth and development. Additionally, developing an antibiotic rotation treatment strategy is necessary to reduce the prevalence of MRMP strains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsDrug Resistance, BacterialMacrolidesMycoplasma pneumoniaePneumonia, MycoplasmaChildChild, PreschoolFemaleHumansMaleCommunity-Acquired InfectionsConsensus

Stichwörter der Autor:innen

ChildDiagnosisMacrolide-resistant Mycoplasma pneumoniaeRecommendationTreatment

Substanzen

Anti-Bacterial AgentsMacrolides

Autor:innen und Institutionen

  • Department of Pulmonology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China.
  • Department of Child Health Care, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China.
  • Department of Pediatric Pulmonology and Immunology, West China Second University Hospital, Sichuan University, Chengdu 610041, China.
  • Department of Pediatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
  • Department of Pulmonology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200062, China.
  • Department of Pulmonary and Critical Care Medicine, Kunming Children's Hospital, Kunming 650034, China.

ORCID-Profile: Zhi-Min Chen

Förderung

  • Key R & D Projects of Zhejiang Province

Zitieren

APA

Wang, Y. S., Zhou, Y. L., Bai, G. N., Li, S. X., Xu, D., Chen, L. N., Chen, X., Dong, X. Y., Fu, H. M., Fu, Z., Hao, C. L., Hong, J. G., Liu, E. M., Liu, H. M., Lu, X. X., Luo, Z. X., Tang, L. F., Tian, M., Yin, Y., …, & Chen, Z. M. (2024). Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. World Journal of Pediatrics, 20(9), 901-914. https://doi.org/10.1007/s12519-024-00831-0

Vancouver

Wang YS, Zhou YL, Bai GN, Li SX, Xu D, Chen LN, et al. Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. World Journal of Pediatrics. 2024;20(9):901-914. doi:10.1007/s12519-024-00831-0

BibTeX
@article{Wang2024,
  author = {Wang, Ying-Shuo and Zhou, Yun-Lian and Bai, Guan-Nan and Li, Shu-Xian and Xu, Dan and Chen, Li-Na and Chen, Xing and Dong, Xiao-Yan and Fu, Hong-Min and Fu, Zhou and Hao, Chuang-Li and Hong, Jian-Guo and Liu, En-Mei and Liu, Han-Min and Lu, Xiao-Xia and Luo, Zheng-Xiu and Tang, Lan-Fang and Tian, Man and Yin, Yong and Zhang, Xiao-Bo and Zhang, Jian-Hua and Zhang, Hai-Lin and Zhao, De-Yu and Zhao, Shun-Ying and Zhu, Guo-Hong and Zou, Ying-Xue and Lu, Quan and Zhang, Yuan-Yuan and Chen, Zhi-Min},
  title = {Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children},
  journal = {World Journal of Pediatrics},
  year = {2024},
  volume = {20},
  number = {9},
  pages = {901--914},
  doi = {10.1007/s12519-024-00831-0}
}
Kostenlos starten →